Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Monopar Therapeutics Inc MNPR

Healthcare Biotechnology
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr... see more

Recent & Breaking News (NDAQ:MNPR)

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

GlobeNewswire November 8, 2024

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

GlobeNewswire October 30, 2024

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

GlobeNewswire October 28, 2024

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire October 28, 2024

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

GlobeNewswire October 24, 2024

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

GlobeNewswire October 22, 2024

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

GlobeNewswire October 15, 2024

Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

GlobeNewswire October 7, 2024

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

GlobeNewswire September 12, 2024

Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

GlobeNewswire August 27, 2024

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

GlobeNewswire August 21, 2024

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

GlobeNewswire August 14, 2024

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

GlobeNewswire August 9, 2024

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

GlobeNewswire August 9, 2024

Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

GlobeNewswire July 9, 2024

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

GlobeNewswire June 25, 2024

Monopar and NorthStar Amend & Extend Collaboration

GlobeNewswire June 11, 2024

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

GlobeNewswire June 10, 2024

Monopar Announces CFO Succession

GlobeNewswire May 24, 2024